SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 30, 2004
GENTA
INCORPORATED
(Exact Name of
Registrant as Specified in Its Charter)
Delaware
(State or Other
Jurisdiction of Incorporation)
| 0-19635 | 33-0326866 | ||
| (Commission File Number) | (IRS Employer Identification No.) | ||
| Two
Connell Drive Berkeley Heights, NJ 07922 |
07922 | ||
| (Address of Principal Executive Offices) | (Zip Code) |
(908) 286-9800
(Registrant’s
Telephone Number, Including Area Code)
(Former Name or
Former Address, if Changed Since Last Report)
Item 12. Results of Operations and Financial Condition.
On
April 30, 2004, Genta Incorporated (“Genta”) issued a press release
announcing that the United States Food and Drug Administration (FDA) has posted
on its website briefing documents for the Oncologic Drugs Advisory Committee
(ODAC) meeting on Monday, May 3, 2004. The press release is attached hereto as
Exhibit 99.1. Genta does not intend for this Item 12 or Exhibit 99.1 to be
treated as “filed” under the Securities Exchange Act of 1934, as
amended, or incorporated by reference into its filings under the Securities Act
of 1933, as amended.
| Exhibit Number |
Description | |
|
|
|
|
| 99.1 | Press Release dated April 30, 2004 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| GENTA INCORPORATED | ||||
| Date: | April 30, 2004 | By: | /s/ William P. Keane | |
| |
|
|||
| Name: |
William P. Keane | |||
| Title: | Vice President, Chief Financial Officer and Corporate Secretary | |||
EXHIBIT INDEX
| Exhibit Number |
Description |
Sequentially Numbered Page |
|
| 99.1 | Press Release dated April 30, 2004 |